Bayer Faces Over 2,000 Lawsuits In Wake Of Lipobay Scandal

Jan. 13, 2005
By Agence France-Presse German pharmaceuticals giant Bayer AG said Aug. 7 it was facing more than 2,000 lawsuits in the wake of a scandal surrounding its disgraced anti-cholesterol drug Lipobay/Baycol, which is suspected of having caused the deaths of ...
By Agence France-Presse German pharmaceuticals giant Bayer AG said Aug. 7 it was facing more than 2,000 lawsuits in the wake of a scandal surrounding its disgraced anti-cholesterol drug Lipobay/Baycol, which is suspected of having caused the deaths of around 100 people. Most of the lawsuits had been filed in the United States, said Bayer spokesman Guenter Forneck. "There are 36 suits outside the U.S.," he added. The number of suits filed is not necessarily equivalent to the number of people actually suing the Leverkusen-based company, since it also includes class-action suits filed on behalf of groups of individuals. Bayer was forced to pull Lipobay, previously regarded as one of its most promising drugs, from the market in August 2001, plunging the hitherto highly profitable pharmaceuticals group into financial crisis. Copyright Agence France-Presse, 2002

Popular Sponsored Recommendations

How Manufacturers Can Optimize Operations with Weather Intelligence

Nov. 2, 2023
The bad news? Severe weather has emerged as one of the biggest threats to continuity and safety in manufacturing. The good news? The intelligence solutions that build weather ...

The Benefits of Continuous Thermal Monitoring

Oct. 17, 2023
Read this eBook to learn more about collecting and using data intelligently to improve performance.

Shifting Your Business from Products to Service-Based Business Models: Generating Predictable Revenues

Oct. 27, 2023
Executive summary on a recent IndustryWeek-hosted webinar sponsored by SAP

Legacy Phone Lines Are Draining Your Profits

Oct. 30, 2023
Copper wire phone line expenses that support emergency devices could be costing your company millions of dollars in wasteful overhead expenses. Rates have been skyrocketing while...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!